Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 5 recruiting now full pipeline small index

Pituitary Adenoma: full-pipeline trial registry

5 of 10 indexed Pituitary Adenoma trials are currently recruiting.

Corpus placement: #1,724 of 28,707 conditions by registered trial count.

10 US clinical trials · 5 currently recruiting · #1,724 of 28,707 conditions by registered trial count

Pituitary Adenoma: 10 US clinical trials tracked, 5 recruiting.

Pituitary Adenoma is the subject of 10 registered US clinical trials on ClinicalTrials.gov, 5 of them currently open to new participants. 3 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is Mayo Clinic, running 2 of these trials.

Enrollment posture brief

Registry condition pituitary-adenoma

OPEN 5 | RECR 50% | LATE 3 | EARLY 2 | RANK #1724 | SPON 2

Nearest open-share peer: Abdominal Aortic Aneurysms (50% recruiting · 6 trials)

Acute Leukemia of Ambiguous 80%Pituitary Adenoma (this)50%Achondroplasia40%Accelerated Phase Chronic My20%Accidental Fall20%
Open-enrollment share among volume-matched conditions near Pituitary Adenoma

Pituitary Adenoma lists 5 open slots (50% of 10 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Pituitary Adenoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Pituitary Adenoma is recruiting above its size-band peers.

    5 of 10 indexed trials (50%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Pituitary Adenoma research.

    Mayo Clinic accounts for 2 of 10 trials (20%). 9 distinct sponsors appear on at least one study for this condition label.

  3. Typical Pituitary Adenoma enrolment sits around 116 participants.

    Median target enrolment is 116 among the 10 trials that report a genuine target (sentinel values excluded). 4 of those (40%) plan for fewer than 100 participants.

  4. Pituitary Adenoma splits between interventional and observational designs.

    6 interventional and 4 observational studies make up this index (60% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 12Phase 43

Open and recent trials

10 total, page 1 of 1

RECRUITING Phase 4 200 participants

68-Ga DOTATATE PET/MRI in the Diagnosis and Management of Somatostatin Receptor Positive CNS Tumors.

Weill Medical College of Cornell University

NCT04081701

RECRUITING Phase 4 116 participants

Prophylactic Oral Antibiotics on Sinonasal Outcomes Following Endoscopic Transsphenoidal Surgery for Pituitary Lesions

St. Joseph's Hospital and Medical Center, Phoenix

NCT03014687

RECRUITING 110 participants

Evaluation of Intraoperative Contrast Enhanced Ultrasound for the Identification of Pituitary Adenoma in Cushing's Disease Compared to Other Pituitary Tumors

Mayo Clinic

NCT07335315

RECRUITING NA 22 participants

DDAVP for Pituitary Adenoma

National Institute of Neurological Disorders and Stroke (NINDS)

NCT04569591

RECRUITING Phase 1 5 participants

Use of [18F] Fluoroethyl-L-tyrosine PET/MRI for Identifying Small Functional Pituitary Adenomas

Mayo Clinic

NCT07456878

ACTIVE NOT RECRUITING Phase 1 17 participants

A First in Human Study Using 89Zr-cRGDY Ultrasmall Silica Particle Tracers for Malignant Brain Tumors

Memorial Sloan Kettering Cancer Center

NCT03465618

COMPLETED 1,387 participants

Defining the Genetic Basis for the Development of Primary Pigmented Nodular Adrenocortical Disease (PPNAD) and the Carney Complex

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

NCT00001452

COMPLETED 408 participants

Multicentric Prospective Validation of the Zurich Pituitary Score

University of Zurich

NCT04076046

COMPLETED 292 participants

Prospective Study of Clinically Nonfunctioning Pituitary Adenomas

Columbia University

NCT01556230

COMPLETED Phase 4 41 participants

Surgical Debulking of Pituitary Adenomas

NYU Langone Health

NCT01371643

Phase Distribution

PhaseTrial count
Phase 1 2
Phase 4 3

Named interventions

Most-linked intervention names on Pituitary Adenoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

oCRH Drug
1 trials
Radiotherapy for CNFA Radiation
1 trials
Surgical intervention for CNFA Procedure
1 trials
transsphenoidal surgery Procedure
1 trials
Blood and Urine samples Other
1 trials
89Zr-DFO-cRGDY-PEG-Cy5-C' dots PET Imaging Drug
1 trials
FET-PET/MRI Drug
1 trials
Octreotide LAR Drug
1 trials

US sites by state

Facility locations filed on Pituitary Adenoma trials. A trial with sites in several states counts in each.

New York 5 trials
Maryland 2 trials
Minnesota 1 trials
Florida 1 trials
Arizona 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Pituitary Adenoma page

10 registered trials, 5 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • 5 Pituitary Adenoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
  • Mayo Clinic sponsors the most Pituitary Adenoma trials on record, review their full trial history before evaluating a specific study. See Mayo Clinic's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Pituitary Adenoma condition card totals 10 registered trials; most-linked intervention oCRH; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.